MABSILICO

MAbSilico is a leading TechBio company specializing in the computational discovery and optimization of therapeutic antibodies. By leveraging advanced Artificial Intelligence and molecular modeling, the platform simulates interactions between antibodies and their targets with high-speed precision.

The core mission is to drastically reduce the time and costs associated with traditional biotech R&D. By replacing lengthy, expensive “wet lab” experiments with high-performance in silico simulations, MAbSilico identifies the most promising drug candidates at the earliest stages. Its software suite covers critical needs such as epitope mapping, affinity prediction, and developability assessment.

As a strategic partner for pharma and biotech firms, MAbSilico transforms biological testing into a predictive science, accelerating the delivery of innovative treatments to patients worldwide.